(Q30318419)

English

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 November 2017

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel (English)

1 reference

Europe PubMed Central

5 November 2017

phase III clinical trial

0 references

Gunter von Minckwitz

11

0 references

15

object named as

Nadia Harbeck

0 references

object named as

Fred Sweep

10

0 references

Eva Johanna Kantelhardt

1

object named as

Eva J Kantelhardt

1 reference

Europe PubMed Central

5 November 2017

author name string

Martina Vetter

2

1 reference

Europe PubMed Central

5 November 2017

Marcus Schmidt

3

1 reference

Europe PubMed Central

5 November 2017

Corinne Veyret

4

1 reference

Europe PubMed Central

5 November 2017

Doris Augustin

5

1 reference

Europe PubMed Central

5 November 2017

Volker Hanf

6

1 reference

Europe PubMed Central

5 November 2017

Christoph Meisner

7

1 reference

Europe PubMed Central

5 November 2017

Daniela Paepke

8

1 reference

Europe PubMed Central

5 November 2017

Manfred Schmitt

9

1 reference

Europe PubMed Central

5 November 2017

Pierre-Marie Martin

12

1 reference

Europe PubMed Central

5 November 2017

Fritz Jaenicke

13

1 reference

Europe PubMed Central

5 November 2017

Christoph Thomssen

14

1 reference

Europe PubMed Central

5 November 2017

language of work or name

0 references

publication date

16 April 2011

1 reference

Europe PubMed Central

5 November 2017

1 reference

Europe PubMed Central

5 November 2017

11

1 reference

Europe PubMed Central

5 November 2017

140

1 reference

Europe PubMed Central

5 November 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-11-140

0 references

Emerging biomarkers in breast cancer care

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Personalized treatment of early-stage breast cancer: present concepts and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Clinical application of the 70-gene profile: the MINDACT trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Clinical relevance of prognostic factors in axillary node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Prognostic impact of tumor biological factors on survival in node-negative breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

How to use prognostic factors in axillary node-negative breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

3 June 2018

Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-140

21 January 2018

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol I

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-140

21 January 2018

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-140

21 January 2018

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-140

21 January 2018

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

26 November 2018

Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3089797

26 November 2018

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21496284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Do we need better prognostic factors in node-negative breast cancer? Pro:

1 reference

https://pubmed.ncbi.nlm.nih.gov/21496284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21496284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21496284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://pubmed.ncbi.nlm.nih.gov/21496284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse

1 reference

https://pubmed.ncbi.nlm.nih.gov/21496284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens

1 reference

https://pubmed.ncbi.nlm.nih.gov/21496284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-11-140

1 reference

Europe PubMed Central

5 November 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

5 November 2017

1 reference

Europe PubMed Central

5 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30318419&oldid=1985100734"